Endocyte raises $26 million to fund clinical anticancer pipeline
This article was originally published in Scrip
Endocyte has raised $26 million in an extension of its series C financing. The US biotechnology company has a broad pipeline of drug candidates for the treatment of various cancers and inflammatory diseases, including six anticancer drugs in clinical trials.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.